Neomycin

Neomycin
Clinical data
Trade names	Neo-rx
AHFS/Drugs.com	Monograph
MedlinePlus	a682274
Routes of; administration	Topical, oral
ATC code	A01AB08 (WHO) A07AA01 (WHO), B05CA09 (WHO), D06AX04 (WHO), J01GB05 (WHO), R02AB01 (WHO), S01AA03 (WHO), S02AA07 (WHO), S03AA01 (WHO);
Legal status
Legal status	US: ℞-only but OTC in Neosporin and similar ointments;
Pharmacokinetic data
Bioavailability	None
Protein binding	N/A
Metabolism	N/A
Elimination half-life	2 to 3 hours
Identifiers
	IUPAC name (2RS,3S,4S,5R)-5-Amino-2-(aminomethyl)-6-((2R,3S,4R,5S)-5-((1R,2R,5R,6R)-3,5-diamino-2-((2R,3S,4R,5S)-3-amino-6-(aminomethyl)-4,5-dihydroxytetrahydro-2H-pyran-2-yloxy)-6-hydroxycyclohexyloxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yloxy)tetrahydro-2H-pyran-3,4-diol;
CAS Number	1404-04-2 ;
PubChem CID	8378;
IUPHAR/BPS	709;
DrugBank	DB00994 ;
ChemSpider	8075 ;
UNII	I16QD7X297;
KEGG	D08260 ;
ChEBI	CHEBI:7508 ;
ChEMBL	ChEMBL449118 ;
ECHA InfoCard	100.014.333
Chemical and physical data
Formula	C23H46N6O13
Molar mass	614.650 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O([C@H]3[C@H](O[C@@H]2O[C@H](CO)[C@@H](O[C@H]1O[C@@H](CN)[C@@H](O)[C@H](O)[C@H]1N)[C@H]2O)[C@@H](O)[C@H](N)C[C@@H]3N)[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4N)CN;
	InChI InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7+,8?,9+,10+,11-,12+,13+,14-,15+,16-,17+,18-,19+,20-,21+,22-,23-/m0/s1 ; Key:PGBHMTALBVVCIT-DPNHOFNISA-N ;
	(what is this?) (verify)

Neomycin, also known as framycetin, is an aminoglycoside antibiotic that displays bactericidal activity against Gram-negative aerobic bacilli and some anaerobic bacilli where resistance has not yet arisen. It is generally not effective against Gram-positive bacilli and anaerobic Gram-negative bacilli. Neomycin comes in oral and topical formulations, including creams, ointments, and eyedrops. Neomycin belongs to the aminoglycoside class of antibiotics that contain two or more amino sugars connected by glycosidic bonds.

Neomycin was discovered in 1949 by microbiologist Selman Waksman and his student Hubert Lechevalier at Rutgers University. Neomycin received approval for medical use in 1952.^[1] Rutgers University was granted the patent for neomycin in 1957.^[2]

^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 507. ISBN 9783527607495. Archived from the original on 2020-08-01. Retrieved 2020-05-25.
^ US 2799620, Waksman SA, Lechevalier HA, "Neomycin and process of preparation", issued 18 July 1957, assigned to Rutgers Research and Educational Foundation.

[Fis2006-1] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 507. ISBN 9783527607495. Archived from the original on 2020-08-01. Retrieved 2020-05-25.

[2] US 2799620, Waksman SA, Lechevalier HA, "Neomycin and process of preparation", issued 18 July 1957, assigned to Rutgers Research and Educational Foundation.

[1]

[2]